TY - JOUR
T1 - Immune responses during COVID-19 breakthrough cases in vaccinated children and adolescents
AU - Rivera-Pérez, Daniela
AU - Méndez, Constanza
AU - Diethelm-Varela, Benjamín
AU - Melo-González, Felipe
AU - Vázquez, Yaneisi
AU - Meng, Xing
AU - Xin, Qianqian
AU - Fasce, Rodrigo A.
AU - Fernández, Jorge
AU - Mora, Judith
AU - Ramirez, Eugenio
AU - Acevedo, Mónica L.
AU - Valiente-Echeverría, Fernando
AU - Soto-Rifo, Ricardo
AU - Grifoni, Alba
AU - Weiskopf, Daniela
AU - Sette, Alessandro
AU - Astudillo, Patricio
AU - Le Corre, Nicole
AU - Abarca, Katia
AU - Perret, Cecilia
AU - González, Pablo A.
AU - Soto, Jorge A.
AU - Bueno, Susan M.
AU - Kalergis, Alexis M.
N1 - Publisher Copyright:
Copyright © 2024 Rivera-Pérez, Méndez, Diethelm-Varela, Melo-González, Vázquez, Meng, Xin, Fasce, Fernández, Mora, Ramirez, Acevedo, Valiente-Echeverría, Soto-Rifo, Grifoni, Weiskopf, Sette, Astudillo, Le Corre, Abarca, Perret, González, Soto, Bueno and Kalergis.
PY - 2024
Y1 - 2024
N2 - Background: Vaccine effectiveness against SARS-CoV-2 infection has been somewhat limited due to the widespread dissemination of the Omicron variant, its subvariants, and the immune response dynamics of the naturally infected with the virus. Methods: Twelve subjects between 3-17 years old (yo), vaccinated with two doses of CoronaVac®, were followed and diagnosed as breakthrough cases starting 14 days after receiving the second dose. Total IgGs against different SARS-CoV-2 proteins and the neutralizing capacity of these antibodies after infection were measured in plasma. The activation of CD4+ and CD8+ T cells was evaluated in peripheral blood mononuclear cells stimulated with peptides derived from the proteins from the wild-type (WT) virus and Omicron subvariants by flow cytometry, as well as different cytokines secretion by a Multiplex assay. Results: 2 to 8 weeks post-infection, compared to 4 weeks after 2nd dose of vaccine, there was a 146.5-fold increase in neutralizing antibody titers against Omicron and a 38.7-fold increase against WT SARS-CoV-2. Subjects showed an increase in total IgG levels against the S1, N, M, and NSP8 proteins of the WT virus. Activated CD4+ T cells showed a significant increase in response to the BA.2 subvariant (p<0.001). Finally, the secretion of IL-2 and IFN-γ cytokines showed a discreet decrease trend after infection in some subjects. Conclusion: SARS-CoV-2 infection in the pediatric population vaccinated with an inactivated SARS-CoV-2 vaccine produced an increase in neutralizing antibodies against Omicron and increased specific IgG antibodies for different SARS-CoV-2 proteins. CD4+ T cell activation was also increased, suggesting a conserved cellular response against the Omicron subvariants, whereas Th1-type cytokine secretion tended to decrease. Clinical Trial Registration: clinicaltrials.gov
AB - Background: Vaccine effectiveness against SARS-CoV-2 infection has been somewhat limited due to the widespread dissemination of the Omicron variant, its subvariants, and the immune response dynamics of the naturally infected with the virus. Methods: Twelve subjects between 3-17 years old (yo), vaccinated with two doses of CoronaVac®, were followed and diagnosed as breakthrough cases starting 14 days after receiving the second dose. Total IgGs against different SARS-CoV-2 proteins and the neutralizing capacity of these antibodies after infection were measured in plasma. The activation of CD4+ and CD8+ T cells was evaluated in peripheral blood mononuclear cells stimulated with peptides derived from the proteins from the wild-type (WT) virus and Omicron subvariants by flow cytometry, as well as different cytokines secretion by a Multiplex assay. Results: 2 to 8 weeks post-infection, compared to 4 weeks after 2nd dose of vaccine, there was a 146.5-fold increase in neutralizing antibody titers against Omicron and a 38.7-fold increase against WT SARS-CoV-2. Subjects showed an increase in total IgG levels against the S1, N, M, and NSP8 proteins of the WT virus. Activated CD4+ T cells showed a significant increase in response to the BA.2 subvariant (p<0.001). Finally, the secretion of IL-2 and IFN-γ cytokines showed a discreet decrease trend after infection in some subjects. Conclusion: SARS-CoV-2 infection in the pediatric population vaccinated with an inactivated SARS-CoV-2 vaccine produced an increase in neutralizing antibodies against Omicron and increased specific IgG antibodies for different SARS-CoV-2 proteins. CD4+ T cell activation was also increased, suggesting a conserved cellular response against the Omicron subvariants, whereas Th1-type cytokine secretion tended to decrease. Clinical Trial Registration: clinicaltrials.gov
KW - breakthrough cases
KW - CoronaVac
KW - inactivated SARS-CoV-2 vaccine
KW - omicron variant
KW - pediatric
KW - phase 3 clinical trial
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85194747874&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2024.1372193
DO - 10.3389/fimmu.2024.1372193
M3 - Article
C2 - 38812507
AN - SCOPUS:85194747874
SN - 1664-3224
VL - 15
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 1372193
ER -